Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia
John J.P. Kastelein(QRx Pharma (United States)), Eric de Groot(Amsterdam UMC Location University of Amsterdam), Mieke D. Trip(Amsterdam UMC Location University of Amsterdam), Evan A. Stein(Oncotherapeutics (United States)), Aeilko H. Zwinderman(Amsterdam Neuroscience), Raphaël Duivenvoorden(Radboud University Nijmegen), Frank L.J. Visseren(University Medical Center Utrecht), Fatima Akdim(Amsterdam UMC Location University of Amsterdam), Erik S.G. Stroes(Amsterdam University Medical Centers), Eric J.G. Sijbrands(Erasmus MC), Enrico P. Veltri(United States Nuclear Regulatory Commission), Michiel L. Bots(Utrecht University), Daniel Gaudet(Brigham and Women's Hospital), Anton F. H. Stalenhoef(Translational Therapeutics (United States)), Adéle Marais(South African Heart Association)
Cited by 1,243
Related Papers
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
|European Heart Journal|2021|6.1k
Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews
|Journal of Clinical Epidemiology|2005|3.3k
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society
|European Heart Journal|2013|2.7k
The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes
|Nature Genetics|2000|1.8k